These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36737752)

  • 21. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.
    Fiala O; Hosek P; Korunkova H; Hora M; Kolar J; Windrichova J; Sorejs O; Topolcan O; Travnicek I; Sedlackova H; Finek J
    Anticancer Res; 2023 Jan; 43(1):463-471. PubMed ID: 36585174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
    Pilon D; Queener M; Lefebvre P; Ellis LA
    J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
    Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
    Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
    Bjartell A; Costa L; Kramer G; Zurawski B; Galli L; Werbrouck P; Ecke T; Parikh O; Bennamoun M; Garcia Freire C; Peer A; Ljungberg B; Cicin I; Smith E; Lukac M; Wapenaar R; Chowdhury S
    Eur Urol Open Sci; 2022 Nov; 45():12-22. PubMed ID: 36353661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
    Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
    Tsujino T; Tokushige S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Ohno T; Nakamori K; Maenosono R; Nishimura K; Yamazaki S; Uchimoto T; Yanagisawa T; Mori K; Urabe F; Tsuzuki S; Iwatani K; Yamamoto S; Takahara K; Inamoto T; Kimura T; Ohno Y; Shiroki R; Azuma H
    Cancer Med; 2023 Oct; 12(19):19414-19422. PubMed ID: 37706578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
    Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
    BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
    Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
    Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
    Ternov KK; Sønksen J; Fode M; Lindberg H; Kistorp C; Bisbjerg R; Faber J; Klausen TW; Palapattu G; Østergren PB
    Eur J Cancer; 2022 Aug; 171():75-84. PubMed ID: 35709600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
    Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
    Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
    Boerrigter E; Benoist GE; van Oort IM; Verhaegh GW; van Hooij O; Groen L; Smit F; Oving IM; de Mol P; Smilde TJ; Somford DM; Mehra N; Schalken JA; van Erp NP
    Mol Oncol; 2021 Sep; 15(9):2453-2465. PubMed ID: 33650292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T
    Clin Transl Oncol; 2024 Oct; 26(10):2559-2571. PubMed ID: 38750344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
    Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
    Procopio G; Chiuri VE; Giordano M; Alitto AR; Maisano R; Bordonaro R; Cinieri S; Rossetti S; De Placido S; Airoldi M; Galli L; Gasparro D; Ludovico GM; Guglielmini PF; Carella C; Nova P; Aglietta M; Schips L; Beccaglia P; Sciarra A; Livi L; Santini D;
    ESMO Open; 2022 Apr; 7(2):100431. PubMed ID: 35405438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone.
    Sheng IY; Fallah J; Gupta R; Li H; Allman K; Martin A; Barata P; Ornstein MC; Gilligan TD; Rini BI; Garcia JA
    Target Oncol; 2020 Aug; 15(4):477-483. PubMed ID: 32661959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.